• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
Nairametrics
No Result
View All Result
Home Business News Business

AstraZeneca records breast cancer trial success, boosts oncology credentials

Drug shows prolonged survival while slowing the progression of metastatic breast cancer.

Chidinma Anyalewechi by Chidinma Anyalewechi
February 23, 2022
in Business
AstraZeneca records breast cancer trial success,

AstraZeneca records breast cancer trial success, boosts oncology credentials

Share on FacebookShare on TwitterShare on Linkedin

Drug company, AstraZeneca has said that its “Enhertu” cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a much larger potential patient group.

According to the drugmaker, the drug, Enhertu, has shown prolonged survival while slowing the progression of metastatic breast cancer with low levels of a protein known as HER2.

When compared with standard chemotherapy, the improvement was described as “clinically meaningful”. Meanwhile, detailed results of the late-stage trial would be presented at an as-yet-undisclosed medical conference.

RelatedStories

Cancer

Breast cancer cases to rise 38%, deaths to increase 68% by 2050 – WHO 

February 25, 2025
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

AstraZenaca to launch new COVID-19 prevention drug amid global withdrawal of vaccine 

May 17, 2024

The company has said it would reach out to regulatory agencies to enable a speedy review of a wider use for the drug.

The head of oncology research and development at AstraZeneca, Susan Galbraith said, “This is about redefining the categorisation of breast cancer and increasing the number of options for women”. The study was limited to low-HER2 patients whose tumours had spread to other parts of the body.

She also added that, while the new study had focused on women that had exhausted three to four earlier therapies, more trials would in future test Enhertu on women during earlier stages of the disease, both with high and low HER2, which would be a much larger patient group.

What you should know about Enhertu

  • The Astrazeneca cancer drug, Enhertu, belongs to a promising class of therapies called antibody drug conjugates (ADC), which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.
  • The latest drug, Enhertu, has since been shown to help women with metastatic breast cancer characterised by high levels of HER2, compared to Kadcyla, the ADC drug from Switzerland’s Roche – the world’s biggest cancer drugmaker.
  • This is a welcomed development in the global health sector as thousands of women are diagnosed of this disease yearly and with limited options for survival.

Follow us for Breaking News and Market Intelligence.
Tags: AstraZenecabreast cancer
Chidinma Anyalewechi

Chidinma Anyalewechi

For further inquiries about this article, contact: Email: chidinma.anyalewechi@nairametrics.com LinkedIn: linkedin.com/in/chidinma-anyalewechi-a323ab173/

Related Posts

Cancer
Health

Breast cancer cases to rise 38%, deaths to increase 68% by 2050 – WHO 

February 25, 2025
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 
Health

AstraZenaca to launch new COVID-19 prevention drug amid global withdrawal of vaccine 

May 17, 2024
University of Bristol develops new robot to detect breast cancer early
Health

University of Bristol develops new robot to detect breast cancer early

October 4, 2023
Covid-19: Lagos puts 14 countries on watchlist, to enforce travel protocols
Socio Economic

Lagos says over 1.9 million doses of Covid-19 vaccines administered in the state

December 12, 2021
AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19
Socio Economic

AstraZeneca receives first approval for registration of antiviral cocktail in Australia

November 9, 2021
AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19
Socio Economic

AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

October 12, 2021
Next Post
The 50th anniversary of the Global International Monetary Policy – Issues and Transition

How to make money from the Russian-Ukrainian crisis, but is it the right thing to do?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

first bank








DUNS

Recent News

  • Lagos Govt impounds over 10 trucks above 9 tonnes for violating Third Mainland Bridge ban 
  • Liquidity surge from FAAC raises inflation concerns – Cardoso
  • US imports $1.34 billion Nigerian crude oil in five months despite Trump tariffs

Follow us on social media:

Recent News

LASTMA deploys advanced tow trucks for smooth traffic on Lekki-Ajah as Dangote Refinery commences petrol distribution

Lagos Govt impounds over 10 trucks above 9 tonnes for violating Third Mainland Bridge ban 

July 20, 2025
CBN Governor Yemi Cardoso to be honoured at Nairametrics Capital Market Awards for monetary policy reforms and banking sector recapitalization 

Liquidity surge from FAAC raises inflation concerns – Cardoso

July 20, 2025
  • iOS App
  • Android App
  • Contact Us
  • Home
  • Markets
  • Sectors
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer
  • Copyright Infringement

© 2025 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Login
  • Sign Up

© 2025 Nairametrics